At VM Medical Park Ankara, targeted therapy is offered using state-of-the-art molecular diagnostic instruments and protocols. The JCI accredited facility has been functioning since 2014 and is located in Ankara, Turkey. The hospital has 327 beds and serves both international and local patients.

Targeted therapy is designed to combat cancer by utilising specific characteristics of tumour molecular structure. Based on the biomarker, targeted drugs could be administered to halt the functioning of proteins or biological pathways responsible for causing cancer. The role of the medical staff involved in the procedure is to determine the treatment plan based on factors such as pathology, molecular diagnostic results, disease stage, and previous treatments.